» Articles » PMID: 36836211

Predictive Role of HsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Feb 25
PMID 36836211
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated levels of high-sensitivity C-reactive protein (hsCRP) were associated with an increased risk of recurrent stroke. However, it is still unknown whether the predictive value of hsCRP differed according to the severity of cerebrovascular disease. We used the cohort of the prospective multicenter cohort study of the Third China National Stroke Registry (CNSR-III), in which 10,765 consecutive patients with acute ischemic stroke or transient ischemic attack (TIA) had hsCRP levels measured. Patients were classified into minor stroke, or TIA, and non-minor stroke. The primary outcome was a new stroke within 1 year. Cox proportional hazards models were used to assess the association of hsCRP and its outcome. Elevated levels of hsCRP were associated with an increased risk of recurrent stroke in minor stroke or TIA patients, irrespective of using a National Institutes of Health Stroke Scale (NIHSS) score of ≤3 (the highest quartile vs. the lowest quartile: adjusted hazard ratio, 1.48; 95% CI, 1.12-1.97; = 0.007) or ≤5 (the highest quartile vs. the lowest quartile: adjusted hazard ratio, 1.45; 95% CI, 1.15-1.84; = 0.002) to define minor stroke. Such association was more apparent in the large-artery atherosclerosis subtype. However, for the patients with non-minor stroke, the association of hsCRP with recurrent stroke disappeared.

Citing Articles

Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.

Li J, Meng X, Shi F, Jing J, Gu H, Jin A BMJ. 2024; 385:e079061.

PMID: 38925803 PMC: 11200154. DOI: 10.1136/bmj-2023-079061.

References
1.
Asdaghi N, Wang K, Ciliberti-Vargas M, Gutierrez C, Koch S, Gardener H . Predictors of Thrombolysis Administration in Mild Stroke: Florida-Puerto Rico Collaboration to Reduce Stroke Disparities. Stroke. 2018; 49(3):638-645. PMC: 5829011. DOI: 10.1161/STROKEAHA.117.019341. View

2.
Wang Y, Jing J, Meng X, Pan Y, Wang Y, Zhao X . The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke Vasc Neurol. 2019; 4(3):158-164. PMC: 6812638. DOI: 10.1136/svn-2019-000242. View

3.
Corso G, Bottacchi E, Brusa A, Lia C, Cordera S, Giardini G . Blood C-reactive protein concentration with ABCD² is a better prognostic tool than ABCD² alone. Cerebrovasc Dis. 2011; 32(2):97-105. DOI: 10.1159/000328230. View

4.
Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K . 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3):e46-e110. DOI: 10.1161/STR.0000000000000158. View

5.
Kelly P, Weimar C, Lemmens R, Murphy S, Purroy F, Arsovska A . Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial. Eur Stroke J. 2021; 6(2):222-228. PMC: 8370082. DOI: 10.1177/2396987320972566. View